David Sinclair and Longevity: The Documented Public Record

By
Published Updated Last reviewed
Clinical medical image for celebrities david sinclair: David Sinclair and Longevity: The Documented Public Record

Who Is David Sinclair?

David Sinclair is a professor in the Department of Genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for Biology of Aging Research. He holds a PhD in molecular genetics from the University of New South Wales and completed postdoctoral work at MIT under Leonard Guarente, a pioneer in sirtuin biology. Sinclair has co-founded several biotechnology companies focused on aging, including Sirtris Pharmaceuticals (acquired by GlaxoSmithKline in 2008 for $720 million), Life Biosciences, and Metro Biotech.

His 2019 book Lifespan: Why We Age and Why We Don't Have To became a New York Times bestseller and brought his personal supplement regimen into mainstream conversation. He has also disclosed his protocol on The Joe Rogan Experience, his own Lifespan Podcast, and in interviews with outlets including TIME and 60 Minutes Australia.

At a glance

  • Name: David Sinclair, PhD, AO
  • Known for: Harvard genetics professor, sirtuin and NAD+ researcher, author of Lifespan
  • Confirmed medications (publicly disclosed): NMN (1 g/day), metformin (off-label, 1 g/day, later reduced), resveratrol (1 g/day with yogurt)
  • Drug family: Longevity
  • Status: Confirmed personal use through book, podcasts, and public lectures
  • Disclosure conflicts: Co-founder of companies commercializing NAD+ precursor technology

The Public Record: What Sinclair Has Confirmed

Sinclair's personal protocol disclosures are unusually detailed for a public figure. In Lifespan (Chapter 6) and across multiple podcast episodes, he has confirmed taking the following compounds daily:

Nicotinamide mononucleotide (NMN): 1 gram per day, taken in the morning. Sinclair has stated he mixes NMN powder into yogurt. He has described this as the centerpiece of his regimen, intended to raise NAD+ levels that decline with age.

Resveratrol: 1 gram per day, also mixed with yogurt. Sinclair emphasizes that resveratrol is fat-soluble and requires a lipid carrier for absorption. He has described resveratrol as a sirtuin-activating compound (STAC) that works synergistically with NAD+ precursors.

Metformin: Initially reported as 1 gram per day (off-label, not for diabetes). In later podcast appearances (2021 and 2022), Sinclair noted he reduces or skips metformin on days he exercises, citing data suggesting metformin may blunt exercise-induced mitochondrial adaptations.

He has also mentioned taking vitamin D, vitamin K2, and aspirin (83 mg), though the longevity compounds above constitute the pharmacologically significant portion of his protocol.

Clinical Context: NMN and the NAD+ Hypothesis

The scientific premise behind Sinclair's NMN use rests on a well-documented phenomenon: intracellular NAD+ levels decline with age, and this decline correlates with mitochondrial dysfunction, DNA repair impairment, and sirtuin activity reduction. NAD+ (nicotinamide adenine dinucleotide) functions as a coenzyme in over 500 enzymatic reactions and serves as a substrate for sirtuins (SIRT1-7) and poly(ADP-ribose) polymerases (PARPs).

In mice, NMN supplementation has shown improvements in vascular function, insulin sensitivity, and physical endurance. A 2022 clinical trial in prediabetic women demonstrated that NMN (250 mg/day for 10 weeks) improved skeletal muscle insulin sensitivity and muscle remodeling, as published in Science.

The human evidence base remains early-stage. A 2024 randomized controlled trial in middle-aged adults taking 600 mg or 900 mg NMN daily for 60 days showed modest increases in blood NAD+ levels but did not demonstrate dramatic functional improvements. No large-scale, long-duration RCT has tested 1 g/day NMN (Sinclair's dose) for hard aging endpoints.

The HealthRX Medical Team notes a critical gap: Sinclair's dose of 1 g/day exceeds what has been tested in published human trials. Extrapolating rodent longevity data to human dosing remains speculative regardless of the mechanistic plausibility. NMN is currently sold as a dietary supplement and is not FDA-approved for any indication. In 2022, the FDA issued a decision excluding NMN from the dietary supplement category after a company (Metro Biotech, co-founded by Sinclair) filed an investigational new drug application. This regulatory status remains contested.

Clinical Context: Resveratrol

Resveratrol is a polyphenol found in grape skins, red wine, and certain berries. Sinclair's laboratory published landmark papers in 2003 and 2006 showing that resveratrol extends lifespan in yeast and improves health in obese mice fed a high-fat diet, published in Nature.

The translation to humans has been disappointing. A 2014 JAMA Internal Medicine study of 783 older adults in the Chianti region found no association between urinary resveratrol metabolites and mortality, cardiovascular disease, or cancer incidence. Multiple clinical trials testing resveratrol for metabolic endpoints have produced inconsistent results, with some showing mild improvements in inflammatory markers and others showing no benefit over placebo.

Bioavailability remains a fundamental challenge. Oral resveratrol undergoes extensive first-pass metabolism, and plasma levels after a 1 g dose are extremely low. Whether Sinclair's practice of consuming resveratrol with fat meaningfully improves absorption in a clinically relevant way has not been confirmed in controlled trials.

Clinical Context: Off-Label Metformin

Metformin is an FDA-approved first-line treatment for type 2 diabetes. Its potential longevity applications stem from observational data: a 2014 UK study found that diabetic patients on metformin had slightly lower all-cause mortality than matched non-diabetic controls, a finding that generated significant scientific interest.

The proposed Targeting Aging with Metformin (TAME) trial, led by Nir Barzilai at the Albert Einstein College of Medicine, aims to test whether metformin delays age-related diseases in non-diabetic adults aged 65 to 79. As of 2026, this trial has begun enrollment but results are years away. Metformin activates AMP-activated protein kinase (AMPK), inhibits mitochondrial complex I, and may reduce mTOR signaling, all pathways implicated in aging biology.

Side effects in non-diabetic users include gastrointestinal symptoms (nausea, diarrhea) in approximately 20-30% of patients and, rarely, vitamin B12 deficiency with long-term use. Sinclair's decision to skip metformin on exercise days reflects a genuine clinical tension: a 2019 study in Aging Cell showed that metformin attenuated exercise-induced improvements in skeletal muscle mitochondrial respiration and cardiorespiratory fitness in older adults.

The Disclosure and Conflict Question

Sinclair's transparency about his personal protocol is notable, but the HealthRX Medical Team emphasizes the accompanying financial interests. Sinclair co-founded Metro Biotech, which develops proprietary NAD+ precursor molecules (including MIB-626, an NMN-based drug candidate). He co-founded Life Biosciences, which invested in multiple aging-related startups. He holds patents related to sirtuin-activating compounds.

This does not invalidate his scientific contributions, which include over 200 peer-reviewed publications. It does mean that his public promotion of NMN sits at the intersection of personal conviction, academic research, and commercial interest, a combination that demands scrutiny from consumers and clinicians alike.

The HealthRX Medical Team Take

Sinclair has done more than any single researcher to bring NAD+ biology and longevity pharmacology into public awareness. His personal protocol of NMN (1 g/day), resveratrol (1 g/day), and metformin (intermittent, off-label) represents a reasonable hypothesis grounded in real mechanistic science. The problem is the distance between hypothesis and proof.

NMN raises NAD+ levels in humans. Whether raising NAD+ levels translates to slower aging, reduced disease incidence, or extended lifespan in humans remains unproven. Resveratrol's human evidence is weak despite strong preclinical data. Metformin's longevity potential awaits the TAME trial.

For consumers considering these compounds, three clinical points matter. First, NMN's regulatory status is uncertain, and product quality varies widely in the supplement market. Second, resveratrol at 1 g/day is pharmacologically aggressive given the limited absorption and mixed trial data. Third, off-label metformin requires a prescription and medical monitoring, particularly for renal function and B12 levels.

Sinclair is transparent about what he takes. He is also transparent that his protocol is not medical advice. The HealthRX Medical Team agrees: these are compounds worth watching as clinical data matures, but the evidence does not yet support recommending them as a longevity stack for the general public.

Frequently asked questions

›
›
›
›
›

References